EU regulator begins real-time review of GSK-Vir COVID-19 antibody drug

EU regulator begins real-time review of GSK-Vir's COVID-19 antibody drug

© Reuters. FILE PHOTO: A general view outside the Glaxo Smith Kline pharmaceutical company headquarters in West London following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 5, 2020. REUTERS/Toby Melville/File Photo

(Reuters) – Europe’s medicines regulator said on Friday it has begun a real-time review of GSK and Vir Biotechnology’s antibody treatment for COVID-19, formally kicking off the process for a potential European Union approval.

The European Medicines Agency said decision for the rolling review was based on early results from an ongoing study into how well the medicine, termed sotrovimab or VIR-7831, can prevent hospitalisation or death in non-hospitalised COVID-19 patients.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

READ SOURCE